Fiera Capital Corp Acquires 163,197 Shares of Biohaven Ltd. $BHVN

Fiera Capital Corp increased its position in shares of Biohaven Ltd. (NYSE:BHVN) by 29.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 724,551 shares of the company’s stock after acquiring an additional 163,197 shares during the period. Fiera Capital Corp owned about 0.68% of Biohaven worth $8,180,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BHVN. PNC Financial Services Group Inc. lifted its holdings in Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares during the period. EverSource Wealth Advisors LLC raised its stake in Biohaven by 178.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after buying an additional 2,583 shares during the period. IFP Advisors Inc raised its stake in Biohaven by 55.4% during the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after buying an additional 1,450 shares during the period. Focus Partners Wealth acquired a new position in Biohaven during the 3rd quarter worth approximately $87,000. Finally, Leonteq Securities AG acquired a new position in Biohaven during the 4th quarter worth approximately $78,000. Institutional investors own 88.78% of the company’s stock.

Biohaven Stock Performance

BHVN stock opened at $11.11 on Wednesday. The firm has a market cap of $1.67 billion, a PE ratio of -1.96 and a beta of 1.35. The company has a quick ratio of 7.41, a current ratio of 7.41 and a debt-to-equity ratio of 1.87. The business has a 50 day moving average of $9.84 and a 200-day moving average of $10.47. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). As a group, sell-side analysts expect that Biohaven Ltd. will post -3.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research note on Wednesday, May 27th. Morgan Stanley dropped their price target on Biohaven from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. TD Cowen upped their price target on Biohaven from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Finally, Citigroup upped their price target on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Biohaven currently has a consensus rating of “Moderate Buy” and an average target price of $22.27.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.